Skip to content
S2Medical

Evidence

References

Every quantitative claim on this site carries a marker to one of the sources below. A claim without a source is not published.

  1. [1]Zattarin E, et al. Materials Today Bio 2025;32:101756.
  2. [2]Bengtsson T, et al. Scientific Reports 2020;10:3580 (Tab. 2B, 4, 6).Co-authored by S2Medical founders.
  3. [3]Khalaf H, et al. BMC Microbiology 2016;16:188.
  4. [4]Musa M, et al. Scientific Reports 2021;11:12514.
  5. [5]Omer A, et al. PLoS One 2022;17:e0278419.
  6. [6]S2Medical press release 2 January 2023: HeAliX (Linköping University, Örebro University, Luleå University of Technology).
  7. [7]EP3755363B9 / EP4056195B1 (WO2019162301A1); US12064464B2.
  8. [8]Literature figure, cited in Scientific Reports 2020 (ref 23); see also Cavallo I, et al. IJMS 2024.
  9. [9]Khamise A, et al. JPRAS 2024;95:55–61.
  10. [10]Shanks J, et al. Scars, Burns & Healing 2020;6.
  11. [11]Karlsson M, et al. Burns 2022;48:1236–45.
  12. [12]Qureshi A, et al. Burns Open 2021;5:17–23.
  13. [13]Hartrick C, et al. JPRAS Open 2026;48:56–64.
  14. [14]S2Medical study register (peer-reviewed clinical publications).

Preclinical qualifiers are part of each claim: in vitro, preclinical porcine model and retrospective are never omitted. No human efficacy data exist for Admercin™. EPIPROTECT® is comparable to porcine xenograft in a randomised controlled trial: not superior.